- Home
- ASTC vs KTRA Comparison
ASTC vs KTRA Comparison
Compare ASTC & KTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTC
- KTRA
- Stock Information
- Founded
- ASTC 1984
- KTRA 2009
- Country
- ASTC United States
- KTRA United States
- Employees
- ASTC N/A
- KTRA N/A
- Industry
- ASTC Biotechnology: Laboratory Analytical Instruments
- KTRA Biotechnology: Pharmaceutical Preparations
- Sector
- ASTC Industrials
- KTRA Health Care
- Exchange
- ASTC Nasdaq
- KTRA Nasdaq
- Market Cap
- ASTC 17.3M
- KTRA 9.6M
- IPO Year
- ASTC 1995
- KTRA N/A
- Fundamental
- Price
- ASTC $10.17
- KTRA $0.17
- Analyst Decision
- ASTC
- KTRA
- Analyst Count
- ASTC 0
- KTRA 0
- Target Price
- ASTC N/A
- KTRA N/A
- AVG Volume (30 Days)
- ASTC 55.9K
- KTRA 1.4M
- Earning Date
- ASTC 09-26-2024
- KTRA 09-16-2024
- Dividend Yield
- ASTC N/A
- KTRA N/A
- EPS Growth
- ASTC N/A
- KTRA N/A
- EPS
- ASTC N/A
- KTRA N/A
- Revenue
- ASTC $2,004,000.00
- KTRA N/A
- Revenue This Year
- ASTC N/A
- KTRA N/A
- Revenue Next Year
- ASTC N/A
- KTRA N/A
- P/E Ratio
- ASTC N/A
- KTRA N/A
- Revenue Growth
- ASTC 456.67
- KTRA N/A
- 52 Week Low
- ASTC $7.00
- KTRA $0.08
- 52 Week High
- ASTC $12.29
- KTRA $4.92
- Technical
- Relative Strength Index (RSI)
- ASTC 52.92
- KTRA 38.06
- Support Level
- ASTC $10.03
- KTRA $0.17
- Resistance Level
- ASTC $12.29
- KTRA $0.24
- Average True Range (ATR)
- ASTC 0.74
- KTRA 0.02
- MACD
- ASTC -0.08
- KTRA -0.00
- Stochastic Oscillator
- ASTC 25.09
- KTRA 7.47
About ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About KTRA Kintara Therapeutics Inc.
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.